nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—Corticosteroid Hormone Receptor Agonists—Prednisone—prostate cancer	0.491	1	CiPCiCtD
Fluocinonide—NR3C1—prostate cancer	0.163	1	CbGaD
Fluocinonide—Ciclesonide—Prednisone—prostate cancer	0.0175	0.0798	CrCrCtD
Fluocinonide—Fluocortolone—Prednisone—prostate cancer	0.0134	0.061	CrCrCtD
Fluocinonide—NR3C1—Prednisone—prostate cancer	0.0132	1	CbGbCtD
Fluocinonide—Amcinonide—Prednisone—prostate cancer	0.0126	0.0577	CrCrCtD
Fluocinonide—Budesonide—Prednisone—prostate cancer	0.0126	0.0577	CrCrCtD
Fluocinonide—Flunisolide—Prednisone—prostate cancer	0.0123	0.0562	CrCrCtD
Fluocinonide—Clobetasol propionate—Prednisone—prostate cancer	0.0123	0.0562	CrCrCtD
Fluocinonide—Desonide—Prednisone—prostate cancer	0.0123	0.0562	CrCrCtD
Fluocinonide—Diflorasone—Prednisone—prostate cancer	0.0123	0.0562	CrCrCtD
Fluocinonide—Paramethasone—Prednisone—prostate cancer	0.012	0.0548	CrCrCtD
Fluocinonide—Desoximetasone—Prednisone—prostate cancer	0.0117	0.0535	CrCrCtD
Fluocinonide—Fluprednidene Acetate—Prednisone—prostate cancer	0.0114	0.0522	CrCrCtD
Fluocinonide—Fluorometholone—Prednisone—prostate cancer	0.0114	0.0522	CrCrCtD
Fluocinonide—Triamcinolone—Prednisone—prostate cancer	0.0114	0.0522	CrCrCtD
Fluocinonide—Mometasone—Prednisone—prostate cancer	0.0114	0.0522	CrCrCtD
Fluocinonide—Dexamethasone—Prednisone—prostate cancer	0.0112	0.051	CrCrCtD
Fluocinonide—Rimexolone—Prednisone—prostate cancer	0.0112	0.051	CrCrCtD
Fluocinonide—Betamethasone—Prednisone—prostate cancer	0.0112	0.051	CrCrCtD
Fluocinonide—Methylprednisolone—Prednisone—prostate cancer	0.0107	0.0488	CrCrCtD
Fluocinonide—SMO—prostate gland—prostate cancer	0.00292	0.171	CbGeAlD
Fluocinonide—SMO—seminal vesicle—prostate cancer	0.00247	0.144	CbGeAlD
Fluocinonide—NR3C1—urine—prostate cancer	0.00196	0.115	CbGeAlD
Fluocinonide—SMO—urethra—prostate cancer	0.00195	0.114	CbGeAlD
Fluocinonide—SMO—testis—prostate cancer	0.00128	0.0752	CbGeAlD
Fluocinonide—SERPINA6—renal system—prostate cancer	0.00109	0.064	CbGeAlD
Fluocinonide—SMO—lymph node—prostate cancer	0.000931	0.0545	CbGeAlD
Fluocinonide—SERPINA6—bone marrow—prostate cancer	0.000827	0.0484	CbGeAlD
Fluocinonide—NR3C1—prostate gland—prostate cancer	0.000703	0.0411	CbGeAlD
Fluocinonide—NR3C1—seminal vesicle—prostate cancer	0.000595	0.0348	CbGeAlD
Fluocinonide—NR3C1—epithelium—prostate cancer	0.000517	0.0302	CbGeAlD
Fluocinonide—NR3C1—renal system—prostate cancer	0.000479	0.028	CbGeAlD
Fluocinonide—NR3C1—urethra—prostate cancer	0.000471	0.0276	CbGeAlD
Fluocinonide—NR3C1—bone marrow—prostate cancer	0.000362	0.0212	CbGeAlD
Fluocinonide—Swelling—Conjugated Estrogens—prostate cancer	0.000313	0.00596	CcSEcCtD
Fluocinonide—Hyperglycaemia—Bicalutamide—prostate cancer	0.000312	0.00594	CcSEcCtD
Fluocinonide—Leukoderma—Epirubicin—prostate cancer	0.000311	0.00592	CcSEcCtD
Fluocinonide—NR3C1—testis—prostate cancer	0.00031	0.0181	CbGeAlD
Fluocinonide—Immune system disorder—Degarelix—prostate cancer	0.00031	0.0059	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Abiraterone—prostate cancer	0.000309	0.00589	CcSEcCtD
Fluocinonide—Dermatitis contact—Estradiol—prostate cancer	0.000301	0.00572	CcSEcCtD
Fluocinonide—Erythema—Degarelix—prostate cancer	0.000298	0.00568	CcSEcCtD
Fluocinonide—Infection—Abiraterone—prostate cancer	0.000296	0.00565	CcSEcCtD
Fluocinonide—Immune system disorder—Cabazitaxel—prostate cancer	0.000292	0.00555	CcSEcCtD
Fluocinonide—Skin exfoliation—Estradiol—prostate cancer	0.00029	0.00553	CcSEcCtD
Fluocinonide—Skin disorder—Abiraterone—prostate cancer	0.00029	0.00552	CcSEcCtD
Fluocinonide—Leukoderma—Doxorubicin—prostate cancer	0.000288	0.00548	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Flutamide—prostate cancer	0.000281	0.00535	CcSEcCtD
Fluocinonide—Erythema—Cabazitaxel—prostate cancer	0.000281	0.00535	CcSEcCtD
Fluocinonide—Amcinonide—ANXA1—prostate cancer	0.000273	0.0978	CrCbGaD
Fluocinonide—Skin disorder—Flutamide—prostate cancer	0.000264	0.00502	CcSEcCtD
Fluocinonide—Dry skin—Goserelin—prostate cancer	0.000255	0.00486	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Degarelix—prostate cancer	0.000252	0.0048	CcSEcCtD
Fluocinonide—Nervous system disorder—Estradiol valerate/Dienogest—prostate cancer	0.000251	0.00478	CcSEcCtD
Fluocinonide—Pain—Estrone—prostate cancer	0.000251	0.00478	CcSEcCtD
Fluocinonide—Swelling—Estradiol—prostate cancer	0.00025	0.00477	CcSEcCtD
Fluocinonide—Immune system disorder—Bicalutamide—prostate cancer	0.00025	0.00476	CcSEcCtD
Fluocinonide—Nasal congestion—Estradiol—prostate cancer	0.000242	0.00462	CcSEcCtD
Fluocinonide—Nervous system disorder—Degarelix—prostate cancer	0.000239	0.00455	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Cabazitaxel—prostate cancer	0.000238	0.00453	CcSEcCtD
Fluocinonide—Skin disorder—Degarelix—prostate cancer	0.000236	0.0045	CcSEcCtD
Fluocinonide—Swelling—Mitoxantrone—prostate cancer	0.000233	0.00444	CcSEcCtD
Fluocinonide—Pain—Nilutamide—prostate cancer	0.000233	0.00444	CcSEcCtD
Fluocinonide—Infection—Cabazitaxel—prostate cancer	0.000228	0.00434	CcSEcCtD
Fluocinonide—Skin exfoliation—Etoposide—prostate cancer	0.000225	0.00429	CcSEcCtD
Fluocinonide—Nervous system disorder—Cabazitaxel—prostate cancer	0.000225	0.00428	CcSEcCtD
Fluocinonide—NR3C1—lymph node—prostate cancer	0.000225	0.0131	CbGeAlD
Fluocinonide—Skin disorder—Cabazitaxel—prostate cancer	0.000223	0.00424	CcSEcCtD
Fluocinonide—Pain—Estradiol valerate/Dienogest—prostate cancer	0.000219	0.00417	CcSEcCtD
Fluocinonide—Pruritus—Estramustine—prostate cancer	0.000217	0.00414	CcSEcCtD
Fluocinonide—Hyperglycaemia—Goserelin—prostate cancer	0.000217	0.00414	CcSEcCtD
Fluocinonide—Hyperglycaemia—Conjugated Estrogens—prostate cancer	0.000215	0.0041	CcSEcCtD
Fluocinonide—Eruption—Epirubicin—prostate cancer	0.000215	0.00409	CcSEcCtD
Fluocinonide—Immune system disorder—Ethinyl Estradiol—prostate cancer	0.000211	0.00403	CcSEcCtD
Fluocinonide—Folliculitis—Epirubicin—prostate cancer	0.00021	0.004	CcSEcCtD
Fluocinonide—Glycosuria—Prednisone—prostate cancer	0.000209	0.00397	CcSEcCtD
Fluocinonide—Pain—Degarelix—prostate cancer	0.000208	0.00397	CcSEcCtD
Fluocinonide—Pruritus—Estrone—prostate cancer	0.000208	0.00395	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Bicalutamide—prostate cancer	0.000204	0.00388	CcSEcCtD
Fluocinonide—Dry skin—Estradiol—prostate cancer	0.000202	0.00385	CcSEcCtD
Fluocinonide—Eruption—Doxorubicin—prostate cancer	0.000199	0.00379	CcSEcCtD
Fluocinonide—Nasopharyngitis—Estradiol—prostate cancer	0.000197	0.00376	CcSEcCtD
Fluocinonide—Pain—Cabazitaxel—prostate cancer	0.000196	0.00374	CcSEcCtD
Fluocinonide—Infection—Bicalutamide—prostate cancer	0.000195	0.00372	CcSEcCtD
Fluocinonide—Folliculitis—Doxorubicin—prostate cancer	0.000195	0.0037	CcSEcCtD
Fluocinonide—Dizziness—Estrone—prostate cancer	0.000194	0.0037	CcSEcCtD
Fluocinonide—Swelling—Etoposide—prostate cancer	0.000194	0.00369	CcSEcCtD
Fluocinonide—Rash—Estramustine—prostate cancer	0.000194	0.00369	CcSEcCtD
Fluocinonide—Dermatitis—Estramustine—prostate cancer	0.000194	0.00369	CcSEcCtD
Fluocinonide—Nervous system disorder—Bicalutamide—prostate cancer	0.000193	0.00368	CcSEcCtD
Fluocinonide—Pruritus—Nilutamide—prostate cancer	0.000193	0.00367	CcSEcCtD
Fluocinonide—Headache—Estramustine—prostate cancer	0.000192	0.00367	CcSEcCtD
Fluocinonide—Pruritus—Flutamide—prostate cancer	0.000192	0.00366	CcSEcCtD
Fluocinonide—Skin disorder—Bicalutamide—prostate cancer	0.000191	0.00364	CcSEcCtD
Fluocinonide—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.000189	0.00359	CcSEcCtD
Fluocinonide—Rash—Abiraterone—prostate cancer	0.000188	0.00358	CcSEcCtD
Fluocinonide—Dermatitis—Abiraterone—prostate cancer	0.000188	0.00358	CcSEcCtD
Fluocinonide—Skin exfoliation—Docetaxel—prostate cancer	0.000187	0.00356	CcSEcCtD
Fluocinonide—Rash—Estrone—prostate cancer	0.000185	0.00352	CcSEcCtD
Fluocinonide—Dermatitis—Estrone—prostate cancer	0.000185	0.00352	CcSEcCtD
Fluocinonide—Headache—Estrone—prostate cancer	0.000184	0.0035	CcSEcCtD
Fluocinonide—Pruritus—Estradiol valerate/Dienogest—prostate cancer	0.000181	0.00345	CcSEcCtD
Fluocinonide—Skin exfoliation—Capecitabine—prostate cancer	0.000181	0.00345	CcSEcCtD
Fluocinonide—Dizziness—Nilutamide—prostate cancer	0.00018	0.00343	CcSEcCtD
Fluocinonide—Dizziness—Flutamide—prostate cancer	0.000179	0.00342	CcSEcCtD
Fluocinonide—Hypersensitivity—Degarelix—prostate cancer	0.000179	0.00342	CcSEcCtD
Fluocinonide—Immune system disorder—Goserelin—prostate cancer	0.000174	0.00331	CcSEcCtD
Fluocinonide—Immune system disorder—Conjugated Estrogens—prostate cancer	0.000172	0.00328	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—prostate cancer	0.000172	0.00328	CcSEcCtD
Fluocinonide—Pruritus—Degarelix—prostate cancer	0.000172	0.00328	CcSEcCtD
Fluocinonide—Hyperglycaemia—Estradiol—prostate cancer	0.000172	0.00328	CcSEcCtD
Fluocinonide—Rash—Nilutamide—prostate cancer	0.000172	0.00327	CcSEcCtD
Fluocinonide—Dermatitis—Nilutamide—prostate cancer	0.000172	0.00327	CcSEcCtD
Fluocinonide—Rash—Flutamide—prostate cancer	0.000171	0.00326	CcSEcCtD
Fluocinonide—Dermatitis—Flutamide—prostate cancer	0.000171	0.00326	CcSEcCtD
Fluocinonide—Headache—Nilutamide—prostate cancer	0.000171	0.00325	CcSEcCtD
Fluocinonide—Headache—Flutamide—prostate cancer	0.00017	0.00324	CcSEcCtD
Fluocinonide—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.000169	0.00323	CcSEcCtD
Fluocinonide—Hypersensitivity—Cabazitaxel—prostate cancer	0.000169	0.00322	CcSEcCtD
Fluocinonide—Pain—Bicalutamide—prostate cancer	0.000168	0.0032	CcSEcCtD
Fluocinonide—Erythema—Goserelin—prostate cancer	0.000168	0.00319	CcSEcCtD
Fluocinonide—Erythema—Conjugated Estrogens—prostate cancer	0.000166	0.00316	CcSEcCtD
Fluocinonide—Infection—Ethinyl Estradiol—prostate cancer	0.000165	0.00315	CcSEcCtD
Fluocinonide—Nervous system disorder—Ethinyl Estradiol—prostate cancer	0.000163	0.00311	CcSEcCtD
Fluocinonide—Glycosuria—Epirubicin—prostate cancer	0.000163	0.00311	CcSEcCtD
Fluocinonide—Skin disorder—Ethinyl Estradiol—prostate cancer	0.000162	0.00308	CcSEcCtD
Fluocinonide—Rash—Estradiol valerate/Dienogest—prostate cancer	0.000161	0.00308	CcSEcCtD
Fluocinonide—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.000161	0.00307	CcSEcCtD
Fluocinonide—Skin exfoliation—Prednisone—prostate cancer	0.000161	0.00307	CcSEcCtD
Fluocinonide—Swelling—Docetaxel—prostate cancer	0.000161	0.00307	CcSEcCtD
Fluocinonide—Dizziness—Degarelix—prostate cancer	0.000161	0.00307	CcSEcCtD
Fluocinonide—Headache—Estradiol valerate/Dienogest—prostate cancer	0.00016	0.00306	CcSEcCtD
Fluocinonide—Hyperglycaemia—Mitoxantrone—prostate cancer	0.00016	0.00305	CcSEcCtD
Fluocinonide—Swelling—Capecitabine—prostate cancer	0.000156	0.00297	CcSEcCtD
Fluocinonide—Rash—Degarelix—prostate cancer	0.000154	0.00292	CcSEcCtD
Fluocinonide—Dermatitis—Degarelix—prostate cancer	0.000153	0.00292	CcSEcCtD
Fluocinonide—Headache—Degarelix—prostate cancer	0.000153	0.00291	CcSEcCtD
Fluocinonide—Dizziness—Cabazitaxel—prostate cancer	0.000152	0.00289	CcSEcCtD
Fluocinonide—Glycosuria—Doxorubicin—prostate cancer	0.000151	0.00287	CcSEcCtD
Fluocinonide—Hypersensitivity—Bicalutamide—prostate cancer	0.000145	0.00276	CcSEcCtD
Fluocinonide—Headache—Cabazitaxel—prostate cancer	0.000144	0.00274	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Goserelin—prostate cancer	0.000142	0.0027	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—prostate cancer	0.00014	0.00268	CcSEcCtD
Fluocinonide—Pruritus—Bicalutamide—prostate cancer	0.000139	0.00265	CcSEcCtD
Fluocinonide—Immune system disorder—Estradiol—prostate cancer	0.000138	0.00263	CcSEcCtD
Fluocinonide—Infection—Goserelin—prostate cancer	0.000136	0.00259	CcSEcCtD
Fluocinonide—Infection—Conjugated Estrogens—prostate cancer	0.000135	0.00257	CcSEcCtD
Fluocinonide—Nervous system disorder—Goserelin—prostate cancer	0.000134	0.00256	CcSEcCtD
Fluocinonide—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.000133	0.00253	CcSEcCtD
Fluocinonide—Erythema—Estradiol—prostate cancer	0.000133	0.00253	CcSEcCtD
Fluocinonide—Skin disorder—Goserelin—prostate cancer	0.000133	0.00253	CcSEcCtD
Fluocinonide—Skin disorder—Conjugated Estrogens—prostate cancer	0.000132	0.00251	CcSEcCtD
Fluocinonide—Dermatitis contact—Epirubicin—prostate cancer	0.000131	0.00249	CcSEcCtD
Fluocinonide—Dry skin—Docetaxel—prostate cancer	0.00013	0.00248	CcSEcCtD
Fluocinonide—Dizziness—Bicalutamide—prostate cancer	0.00013	0.00248	CcSEcCtD
Fluocinonide—Nasopharyngitis—Docetaxel—prostate cancer	0.000127	0.00242	CcSEcCtD
Fluocinonide—Dry skin—Capecitabine—prostate cancer	0.000126	0.0024	CcSEcCtD
Fluocinonide—Skin exfoliation—Epirubicin—prostate cancer	0.000126	0.0024	CcSEcCtD
Fluocinonide—Rash—Bicalutamide—prostate cancer	0.000124	0.00236	CcSEcCtD
Fluocinonide—Dermatitis—Bicalutamide—prostate cancer	0.000124	0.00236	CcSEcCtD
Fluocinonide—Erythema—Mitoxantrone—prostate cancer	0.000124	0.00236	CcSEcCtD
Fluocinonide—Headache—Bicalutamide—prostate cancer	0.000123	0.00235	CcSEcCtD
Fluocinonide—Nasopharyngitis—Capecitabine—prostate cancer	0.000123	0.00234	CcSEcCtD
Fluocinonide—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000123	0.00233	CcSEcCtD
Fluocinonide—Dermatitis contact—Doxorubicin—prostate cancer	0.000121	0.0023	CcSEcCtD
Fluocinonide—Pruritus—Ethinyl Estradiol—prostate cancer	0.000118	0.00224	CcSEcCtD
Fluocinonide—Pain—Goserelin—prostate cancer	0.000117	0.00223	CcSEcCtD
Fluocinonide—Skin exfoliation—Doxorubicin—prostate cancer	0.000117	0.00222	CcSEcCtD
Fluocinonide—Pain—Conjugated Estrogens—prostate cancer	0.000116	0.00221	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.000112	0.00214	CcSEcCtD
Fluocinonide—Dry skin—Prednisone—prostate cancer	0.000112	0.00214	CcSEcCtD
Fluocinonide—Dizziness—Ethinyl Estradiol—prostate cancer	0.00011	0.00209	CcSEcCtD
Fluocinonide—Dexamethasone—CYP3A43—prostate cancer	0.000108	0.0389	CrCbGaD
Fluocinonide—Infection—Estradiol—prostate cancer	0.000108	0.00205	CcSEcCtD
Fluocinonide—Hyperglycaemia—Capecitabine—prostate cancer	0.000107	0.00204	CcSEcCtD
Fluocinonide—Immune system disorder—Etoposide—prostate cancer	0.000107	0.00204	CcSEcCtD
Fluocinonide—Nervous system disorder—Estradiol—prostate cancer	0.000106	0.00203	CcSEcCtD
Fluocinonide—Skin disorder—Estradiol—prostate cancer	0.000105	0.00201	CcSEcCtD
Fluocinonide—Rash—Ethinyl Estradiol—prostate cancer	0.000105	0.002	CcSEcCtD
Fluocinonide—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000105	0.002	CcSEcCtD
Fluocinonide—Headache—Ethinyl Estradiol—prostate cancer	0.000104	0.00198	CcSEcCtD
Fluocinonide—Hypersensitivity—Goserelin—prostate cancer	0.000101	0.00192	CcSEcCtD
Fluocinonide—Infection—Mitoxantrone—prostate cancer	0.0001	0.00191	CcSEcCtD
Fluocinonide—Hypersensitivity—Conjugated Estrogens—prostate cancer	9.99e-05	0.0019	CcSEcCtD
Fluocinonide—Skin disorder—Mitoxantrone—prostate cancer	9.82e-05	0.00187	CcSEcCtD
Fluocinonide—Pruritus—Goserelin—prostate cancer	9.68e-05	0.00184	CcSEcCtD
Fluocinonide—Pruritus—Conjugated Estrogens—prostate cancer	9.59e-05	0.00183	CcSEcCtD
Fluocinonide—Hyperglycaemia—Prednisone—prostate cancer	9.56e-05	0.00182	CcSEcCtD
Fluocinonide—Pain—Estradiol—prostate cancer	9.28e-05	0.00177	CcSEcCtD
Fluocinonide—Difluprednate—NR3C1—prostate cancer	9.17e-05	0.0329	CrCbGaD
Fluocinonide—Dizziness—Goserelin—prostate cancer	9.05e-05	0.00172	CcSEcCtD
Fluocinonide—Dizziness—Conjugated Estrogens—prostate cancer	8.97e-05	0.00171	CcSEcCtD
Fluocinonide—Clocortolone—NR3C1—prostate cancer	8.89e-05	0.0319	CrCbGaD
Fluocinonide—Immune system disorder—Docetaxel—prostate cancer	8.89e-05	0.00169	CcSEcCtD
Fluocinonide—Dry skin—Epirubicin—prostate cancer	8.79e-05	0.00167	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	8.71e-05	0.00166	CcSEcCtD
Fluocinonide—Pain—Mitoxantrone—prostate cancer	8.65e-05	0.00165	CcSEcCtD
Fluocinonide—Rash—Goserelin—prostate cancer	8.63e-05	0.00164	CcSEcCtD
Fluocinonide—Dermatitis—Goserelin—prostate cancer	8.62e-05	0.00164	CcSEcCtD
Fluocinonide—Immune system disorder—Capecitabine—prostate cancer	8.6e-05	0.00164	CcSEcCtD
Fluocinonide—Nasopharyngitis—Epirubicin—prostate cancer	8.58e-05	0.00163	CcSEcCtD
Fluocinonide—Headache—Goserelin—prostate cancer	8.57e-05	0.00163	CcSEcCtD
Fluocinonide—Dexamethasone—ANXA1—prostate cancer	8.57e-05	0.0307	CrCbGaD
Fluocinonide—Erythema—Docetaxel—prostate cancer	8.56e-05	0.00163	CcSEcCtD
Fluocinonide—Rash—Conjugated Estrogens—prostate cancer	8.55e-05	0.00163	CcSEcCtD
Fluocinonide—Dermatitis—Conjugated Estrogens—prostate cancer	8.54e-05	0.00163	CcSEcCtD
Fluocinonide—Headache—Conjugated Estrogens—prostate cancer	8.49e-05	0.00162	CcSEcCtD
Fluocinonide—Desonide—NR3C1—prostate cancer	8.41e-05	0.0302	CrCbGaD
Fluocinonide—Diflorasone—NR3C1—prostate cancer	8.41e-05	0.0302	CrCbGaD
Fluocinonide—Infection—Etoposide—prostate cancer	8.35e-05	0.00159	CcSEcCtD
Fluocinonide—Erythema—Capecitabine—prostate cancer	8.29e-05	0.00158	CcSEcCtD
Fluocinonide—Desoximetasone—NR3C1—prostate cancer	8.2e-05	0.0294	CrCbGaD
Fluocinonide—Skin disorder—Etoposide—prostate cancer	8.17e-05	0.00156	CcSEcCtD
Fluocinonide—Dry skin—Doxorubicin—prostate cancer	8.13e-05	0.00155	CcSEcCtD
Fluocinonide—Hypersensitivity—Estradiol—prostate cancer	7.99e-05	0.00152	CcSEcCtD
Fluocinonide—Nasopharyngitis—Doxorubicin—prostate cancer	7.94e-05	0.00151	CcSEcCtD
Fluocinonide—Pruritus—Estradiol—prostate cancer	7.68e-05	0.00146	CcSEcCtD
Fluocinonide—Beclomethasone—CYP3A5—prostate cancer	7.67e-05	0.0275	CrCbGaD
Fluocinonide—Immune system disorder—Prednisone—prostate cancer	7.66e-05	0.00146	CcSEcCtD
Fluocinonide—Hyperglycaemia—Epirubicin—prostate cancer	7.48e-05	0.00142	CcSEcCtD
Fluocinonide—Hypersensitivity—Mitoxantrone—prostate cancer	7.45e-05	0.00142	CcSEcCtD
Fluocinonide—Erythema—Prednisone—prostate cancer	7.39e-05	0.00141	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	7.24e-05	0.00138	CcSEcCtD
Fluocinonide—Pain—Etoposide—prostate cancer	7.19e-05	0.00137	CcSEcCtD
Fluocinonide—Flurandrenolide—NR3C1—prostate cancer	7.18e-05	0.0258	CrCbGaD
Fluocinonide—Dizziness—Estradiol—prostate cancer	7.18e-05	0.00137	CcSEcCtD
Fluocinonide—Flumethasone Pivalate—NR3C1—prostate cancer	7.06e-05	0.0253	CrCbGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	7.01e-05	0.00134	CcSEcCtD
Fluocinonide—Halobetasol Propionate—NR3C1—prostate cancer	6.95e-05	0.0249	CrCbGaD
Fluocinonide—Infection—Docetaxel—prostate cancer	6.94e-05	0.00132	CcSEcCtD
Fluocinonide—Hyperglycaemia—Doxorubicin—prostate cancer	6.92e-05	0.00132	CcSEcCtD
Fluocinonide—Nervous system disorder—Docetaxel—prostate cancer	6.85e-05	0.00131	CcSEcCtD
Fluocinonide—Rash—Estradiol—prostate cancer	6.84e-05	0.0013	CcSEcCtD
Fluocinonide—Dermatitis—Estradiol—prostate cancer	6.84e-05	0.0013	CcSEcCtD
Fluocinonide—Headache—Estradiol—prostate cancer	6.8e-05	0.00129	CcSEcCtD
Fluocinonide—Skin disorder—Docetaxel—prostate cancer	6.79e-05	0.00129	CcSEcCtD
Fluocinonide—Infection—Capecitabine—prostate cancer	6.72e-05	0.00128	CcSEcCtD
Fluocinonide—Nervous system disorder—Capecitabine—prostate cancer	6.64e-05	0.00126	CcSEcCtD
Fluocinonide—Skin disorder—Capecitabine—prostate cancer	6.57e-05	0.00125	CcSEcCtD
Fluocinonide—Amcinonide—NR3C1—prostate cancer	6.46e-05	0.0232	CrCbGaD
Fluocinonide—Budesonide—NR3C1—prostate cancer	6.46e-05	0.0232	CrCbGaD
Fluocinonide—Rash—Mitoxantrone—prostate cancer	6.37e-05	0.00121	CcSEcCtD
Fluocinonide—Dermatitis—Mitoxantrone—prostate cancer	6.37e-05	0.00121	CcSEcCtD
Fluocinonide—Headache—Mitoxantrone—prostate cancer	6.33e-05	0.00121	CcSEcCtD
Fluocinonide—Fluticasone furoate—NR3C1—prostate cancer	6.33e-05	0.0227	CrCbGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	6.24e-05	0.00119	CcSEcCtD
Fluocinonide—Hypersensitivity—Etoposide—prostate cancer	6.2e-05	0.00118	CcSEcCtD
Fluocinonide—Mometasone—NR3C1—prostate cancer	6.14e-05	0.022	CrCbGaD
Fluocinonide—Rimexolone—NR3C1—prostate cancer	6.07e-05	0.0218	CrCbGaD
Fluocinonide—Immune system disorder—Epirubicin—prostate cancer	5.99e-05	0.00114	CcSEcCtD
Fluocinonide—Infection—Prednisone—prostate cancer	5.99e-05	0.00114	CcSEcCtD
Fluocinonide—Pain—Docetaxel—prostate cancer	5.98e-05	0.00114	CcSEcCtD
Fluocinonide—Pruritus—Etoposide—prostate cancer	5.95e-05	0.00113	CcSEcCtD
Fluocinonide—Nervous system disorder—Prednisone—prostate cancer	5.91e-05	0.00113	CcSEcCtD
Fluocinonide—Skin disorder—Prednisone—prostate cancer	5.85e-05	0.00112	CcSEcCtD
Fluocinonide—Pain—Capecitabine—prostate cancer	5.79e-05	0.0011	CcSEcCtD
Fluocinonide—Erythema—Epirubicin—prostate cancer	5.78e-05	0.0011	CcSEcCtD
Fluocinonide—Beclomethasone—NR3C1—prostate cancer	5.73e-05	0.0205	CrCbGaD
Fluocinonide—Fluocinolone Acetonide—NR3C1—prostate cancer	5.57e-05	0.02	CrCbGaD
Fluocinonide—Dizziness—Etoposide—prostate cancer	5.56e-05	0.00106	CcSEcCtD
Fluocinonide—Immune system disorder—Doxorubicin—prostate cancer	5.55e-05	0.00106	CcSEcCtD
Fluocinonide—Clobetasol propionate—NR3C1—prostate cancer	5.42e-05	0.0194	CrCbGaD
Fluocinonide—Flunisolide—NR3C1—prostate cancer	5.42e-05	0.0194	CrCbGaD
Fluocinonide—Paramethasone—NR3C1—prostate cancer	5.35e-05	0.0192	CrCbGaD
Fluocinonide—Erythema—Doxorubicin—prostate cancer	5.34e-05	0.00102	CcSEcCtD
Fluocinonide—Rash—Etoposide—prostate cancer	5.3e-05	0.00101	CcSEcCtD
Fluocinonide—Dermatitis—Etoposide—prostate cancer	5.3e-05	0.00101	CcSEcCtD
Fluocinonide—Headache—Etoposide—prostate cancer	5.27e-05	0.001	CcSEcCtD
Fluocinonide—Ciclesonide—NR3C1—prostate cancer	5.26e-05	0.0189	CrCbGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—SRC—prostate cancer	5.23e-05	0.00127	CbGpPWpGaD
Fluocinonide—Fluorometholone—NR3C1—prostate cancer	5.22e-05	0.0187	CrCbGaD
Fluocinonide—Hypersensitivity—Docetaxel—prostate cancer	5.15e-05	0.000981	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—PRKACB—prostate cancer	5.11e-05	0.00124	CbGpPWpGaD
Fluocinonide—Fluticasone Propionate—CYP3A5—prostate cancer	5.1e-05	0.0183	CrCbGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—VEGFA—prostate cancer	5.09e-05	0.00123	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—ESR1—prostate cancer	5.08e-05	0.00123	CbGpPWpGaD
Fluocinonide—NR3C1—Circadian Clock—SERPINE1—prostate cancer	5.06e-05	0.00123	CbGpPWpGaD
Fluocinonide—Methylprednisolone—NR3C1—prostate cancer	5.05e-05	0.0181	CrCbGaD
Fluocinonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—prostate cancer	5.05e-05	0.00122	CbGpPWpGaD
Fluocinonide—NR3C1—Transcription factor regulation in adipogenesis—IL6—prostate cancer	5.01e-05	0.00121	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—JUP—prostate cancer	4.99e-05	0.00121	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—WNT4—prostate cancer	4.99e-05	0.00121	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Capecitabine—prostate cancer	4.99e-05	0.00095	CcSEcCtD
Fluocinonide—Pruritus—Docetaxel—prostate cancer	4.94e-05	0.000942	CcSEcCtD
Fluocinonide—Clobetasol propionate—CYP1A1—prostate cancer	4.92e-05	0.0177	CrCbGaD
Fluocinonide—Dexamethasone—CYP17A1—prostate cancer	4.92e-05	0.0177	CrCbGaD
Fluocinonide—NR3C1—Endoderm Differentiation—APC—prostate cancer	4.91e-05	0.00119	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	4.88e-05	0.00093	CcSEcCtD
Fluocinonide—NR3C1—Generic Transcription Pathway—TBX5—prostate cancer	4.86e-05	0.00118	CbGpPWpGaD
Fluocinonide—Pruritus—Capecitabine—prostate cancer	4.79e-05	0.000912	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—RALBP1—prostate cancer	4.76e-05	0.00115	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MC2R—prostate cancer	4.76e-05	0.00115	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—IL1RN—prostate cancer	4.76e-05	0.00115	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—MDM2—prostate cancer	4.72e-05	0.00114	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—NCOA1—prostate cancer	4.7e-05	0.00114	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MYC—prostate cancer	4.68e-05	0.00113	CbGpPWpGaD
Fluocinonide—Infection—Epirubicin—prostate cancer	4.68e-05	0.000892	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TGFB1—prostate cancer	4.67e-05	0.00113	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PTHLH—prostate cancer	4.63e-05	0.00112	CbGpPWpGaD
Fluocinonide—Nervous system disorder—Epirubicin—prostate cancer	4.62e-05	0.000881	CcSEcCtD
Fluocinonide—Dizziness—Docetaxel—prostate cancer	4.62e-05	0.00088	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	4.58e-05	0.00111	CbGpPWpGaD
Fluocinonide—Skin disorder—Epirubicin—prostate cancer	4.58e-05	0.000872	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—PRKACB—prostate cancer	4.53e-05	0.0011	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—prostate cancer	4.52e-05	0.00109	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	4.52e-05	0.000861	CcSEcCtD
Fluocinonide—Dizziness—Capecitabine—prostate cancer	4.47e-05	0.000852	CcSEcCtD
Fluocinonide—NR3C1—Adipogenesis—RXRA—prostate cancer	4.47e-05	0.00108	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Prednisone—prostate cancer	4.44e-05	0.000846	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—PPP3CA—prostate cancer	4.42e-05	0.00107	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—ESR2—prostate cancer	4.41e-05	0.00107	CbGpPWpGaD
Fluocinonide—Rash—Docetaxel—prostate cancer	4.41e-05	0.000839	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—ICAM1—prostate cancer	4.4e-05	0.00107	CbGpPWpGaD
Fluocinonide—Dermatitis—Docetaxel—prostate cancer	4.4e-05	0.000839	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—TH—prostate cancer	4.38e-05	0.00106	CbGpPWpGaD
Fluocinonide—Headache—Docetaxel—prostate cancer	4.38e-05	0.000834	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—ANXA1—prostate cancer	4.35e-05	0.00105	CbGpPWpGaD
Fluocinonide—Infection—Doxorubicin—prostate cancer	4.33e-05	0.000825	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	4.33e-05	0.00105	CbGpPWpGaD
Fluocinonide—Betamethasone—CYP19A1—prostate cancer	4.3e-05	0.0154	CrCbGaD
Fluocinonide—Nervous system disorder—Doxorubicin—prostate cancer	4.28e-05	0.000815	CcSEcCtD
Fluocinonide—Rash—Capecitabine—prostate cancer	4.27e-05	0.000813	CcSEcCtD
Fluocinonide—Pruritus—Prednisone—prostate cancer	4.26e-05	0.000812	CcSEcCtD
Fluocinonide—Dermatitis—Capecitabine—prostate cancer	4.26e-05	0.000812	CcSEcCtD
Fluocinonide—Triamcinolone—NR3C1—prostate cancer	4.26e-05	0.0153	CrCbGaD
Fluocinonide—SMO—Signaling Pathways—PENK—prostate cancer	4.25e-05	0.00103	CbGpPWpGaD
Fluocinonide—Headache—Capecitabine—prostate cancer	4.24e-05	0.000807	CcSEcCtD
Fluocinonide—Skin disorder—Doxorubicin—prostate cancer	4.24e-05	0.000807	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—EGR1—prostate cancer	4.13e-05	0.000999	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CALCA—prostate cancer	4.08e-05	0.000987	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—GSK3B—prostate cancer	4.06e-05	0.000983	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—GHR—prostate cancer	4.05e-05	0.00098	CbGpPWpGaD
Fluocinonide—Pain—Epirubicin—prostate cancer	4.03e-05	0.000768	CcSEcCtD
Fluocinonide—Dizziness—Prednisone—prostate cancer	3.99e-05	0.000759	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—CXCL12—prostate cancer	3.98e-05	0.000964	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	3.98e-05	0.000963	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—prostate cancer	3.96e-05	0.000959	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—GJA1—prostate cancer	3.93e-05	0.000951	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—prostate cancer	3.92e-05	0.000949	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—AR—prostate cancer	3.9e-05	0.000943	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—NRP1—prostate cancer	3.88e-05	0.00094	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—LPL—prostate cancer	3.87e-05	0.000936	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	3.85e-05	0.000931	CbGpPWpGaD
Fluocinonide—Fluticasone Propionate—NR3C1—prostate cancer	3.81e-05	0.0137	CrCbGaD
Fluocinonide—Rash—Prednisone—prostate cancer	3.8e-05	0.000724	CcSEcCtD
Fluocinonide—Dermatitis—Prednisone—prostate cancer	3.8e-05	0.000723	CcSEcCtD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—EP300—prostate cancer	3.79e-05	0.000917	CbGpPWpGaD
Fluocinonide—Headache—Prednisone—prostate cancer	3.78e-05	0.000719	CcSEcCtD
Fluocinonide—Budesonide—CYP3A4—prostate cancer	3.74e-05	0.0134	CrCbGaD
Fluocinonide—Pain—Doxorubicin—prostate cancer	3.73e-05	0.00071	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—SERPINE1—prostate cancer	3.71e-05	0.000899	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—SRC—prostate cancer	3.68e-05	0.000892	CbGpPWpGaD
Fluocinonide—NR3C1—Circadian Clock—EP300—prostate cancer	3.68e-05	0.00089	CbGpPWpGaD
Fluocinonide—Fluticasone furoate—CYP3A4—prostate cancer	3.67e-05	0.0132	CrCbGaD
Fluocinonide—SMO—Signaling by GPCR—PRKCQ—prostate cancer	3.63e-05	0.00088	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—VIP—prostate cancer	3.61e-05	0.000874	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—GNRH1—prostate cancer	3.61e-05	0.000874	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CXCL8—prostate cancer	3.54e-05	0.000856	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—GRP—prostate cancer	3.5e-05	0.000846	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—LPAR1—prostate cancer	3.5e-05	0.000846	CbGpPWpGaD
Fluocinonide—Betamethasone—NR3C1—prostate cancer	3.49e-05	0.0125	CrCbGaD
Fluocinonide—Hypersensitivity—Epirubicin—prostate cancer	3.47e-05	0.000662	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—LRP2—prostate cancer	3.46e-05	0.000838	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PLCB2—prostate cancer	3.46e-05	0.000838	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CDKN1B—prostate cancer	3.45e-05	0.000836	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—PPARA—prostate cancer	3.42e-05	0.000827	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—ADRB2—prostate cancer	3.42e-05	0.000827	CbGpPWpGaD
Fluocinonide—Dexamethasone—CYP1B1—prostate cancer	3.41e-05	0.0122	CrCbGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—IL10—prostate cancer	3.41e-05	0.000824	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CX3CL1—prostate cancer	3.39e-05	0.000822	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—P4HB—prostate cancer	3.39e-05	0.000822	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL2—prostate cancer	3.38e-05	0.000818	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—SSR2—prostate cancer	3.38e-05	0.000818	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—ZNF160—prostate cancer	3.38e-05	0.000818	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—BAZ2A—prostate cancer	3.38e-05	0.000818	CbGpPWpGaD
Fluocinonide—NR3C1—Endoderm Differentiation—CTNNB1—prostate cancer	3.34e-05	0.000808	CbGpPWpGaD
Fluocinonide—Pruritus—Epirubicin—prostate cancer	3.34e-05	0.000635	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—MDM2—prostate cancer	3.33e-05	0.000806	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—VAV3—prostate cancer	3.33e-05	0.000806	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—HIST1H2BG—prostate cancer	3.33e-05	0.000806	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—HIF1A—prostate cancer	3.32e-05	0.000804	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PDE4D—prostate cancer	3.3e-05	0.000799	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—GRB7—prostate cancer	3.3e-05	0.000799	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CCND1—prostate cancer	3.29e-05	0.000797	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CTNNB1—prostate cancer	3.26e-05	0.00079	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	3.25e-05	0.000786	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—LEP—prostate cancer	3.24e-05	0.000785	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—ITPR1—prostate cancer	3.23e-05	0.000782	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—HIST1H4H—prostate cancer	3.22e-05	0.000779	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CXCL8—prostate cancer	3.22e-05	0.000778	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Doxorubicin—prostate cancer	3.21e-05	0.000612	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—MMP9—prostate cancer	3.2e-05	0.000774	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—PTEN—prostate cancer	3.18e-05	0.00077	CbGpPWpGaD
Fluocinonide—Flunisolide—CYP3A4—prostate cancer	3.14e-05	0.0113	CrCbGaD
Fluocinonide—SMO—Signaling Pathways—GNG5—prostate cancer	3.14e-05	0.00076	CbGpPWpGaD
Fluocinonide—Dizziness—Epirubicin—prostate cancer	3.12e-05	0.000594	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—prostate cancer	3.12e-05	0.000754	CbGpPWpGaD
Fluocinonide—Paramethasone—CYP3A4—prostate cancer	3.1e-05	0.0111	CrCbGaD
Fluocinonide—NR3C1—Gene Expression—HNRNPH1—prostate cancer	3.09e-05	0.000748	CbGpPWpGaD
Fluocinonide—Pruritus—Doxorubicin—prostate cancer	3.09e-05	0.000588	CcSEcCtD
Fluocinonide—Ciclesonide—CYP3A4—prostate cancer	3.05e-05	0.0109	CrCbGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—EP300—prostate cancer	3.03e-05	0.000734	CbGpPWpGaD
Fluocinonide—Fluorometholone—CYP3A4—prostate cancer	3.03e-05	0.0109	CrCbGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IL2—prostate cancer	2.98e-05	0.000721	CbGpPWpGaD
Fluocinonide—Rash—Epirubicin—prostate cancer	2.97e-05	0.000566	CcSEcCtD
Fluocinonide—Dermatitis—Epirubicin—prostate cancer	2.97e-05	0.000566	CcSEcCtD
Fluocinonide—Headache—Epirubicin—prostate cancer	2.95e-05	0.000562	CcSEcCtD
Fluocinonide—Methylprednisolone—CYP3A4—prostate cancer	2.93e-05	0.0105	CrCbGaD
Fluocinonide—NR3C1—Adipogenesis—IRS1—prostate cancer	2.89e-05	0.0007	CbGpPWpGaD
Fluocinonide—Dizziness—Doxorubicin—prostate cancer	2.88e-05	0.000549	CcSEcCtD
Fluocinonide—NR3C1—Gene Expression—NFIC—prostate cancer	2.87e-05	0.000695	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—HIF1A—prostate cancer	2.87e-05	0.000695	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—prostate cancer	2.84e-05	0.000686	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—prostate cancer	2.81e-05	0.00068	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—INS—prostate cancer	2.77e-05	0.00067	CbGpPWpGaD
Fluocinonide—Rash—Doxorubicin—prostate cancer	2.75e-05	0.000524	CcSEcCtD
Fluocinonide—Dermatitis—Doxorubicin—prostate cancer	2.75e-05	0.000523	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—PTHLH—prostate cancer	2.74e-05	0.000662	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TGFBR1—prostate cancer	2.74e-05	0.000662	CbGpPWpGaD
Fluocinonide—Headache—Doxorubicin—prostate cancer	2.73e-05	0.00052	CcSEcCtD
Fluocinonide—Dexamethasone—CYP3A5—prostate cancer	2.72e-05	0.00974	CrCbGaD
Fluocinonide—NR3C1—Gene Expression—RPN2—prostate cancer	2.7e-05	0.000654	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—prostate cancer	2.7e-05	0.000653	CbGpPWpGaD
Fluocinonide—NR3C1—Endoderm Differentiation—TGFB1—prostate cancer	2.7e-05	0.000653	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—AKR1C3—prostate cancer	2.69e-05	0.000651	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—IGF1—prostate cancer	2.68e-05	0.000649	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PRKACB—prostate cancer	2.68e-05	0.000648	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—EP300—prostate cancer	2.67e-05	0.000647	CbGpPWpGaD
Fluocinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—prostate cancer	2.66e-05	0.000643	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—MYC—prostate cancer	2.64e-05	0.00064	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—TGFB1—prostate cancer	2.64e-05	0.000638	CbGpPWpGaD
Fluocinonide—Dexamethasone—CYP2A6—prostate cancer	2.63e-05	0.00943	CrCbGaD
Fluocinonide—SMO—Signaling Pathways—PPP3CA—prostate cancer	2.61e-05	0.000632	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—THBS1—prostate cancer	2.61e-05	0.000632	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—NPPA—prostate cancer	2.6e-05	0.000629	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ANXA1—prostate cancer	2.57e-05	0.000623	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—QARS—prostate cancer	2.56e-05	0.00062	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—MED12—prostate cancer	2.55e-05	0.000618	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—SERPINE1—prostate cancer	2.54e-05	0.000616	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PRKCZ—prostate cancer	2.52e-05	0.000611	CbGpPWpGaD
Fluocinonide—Dexamethasone—CYP19A1—prostate cancer	2.5e-05	0.00898	CrCbGaD
Fluocinonide—Triamcinolone—CYP3A4—prostate cancer	2.47e-05	0.00885	CrCbGaD
Fluocinonide—SMO—Signaling Pathways—FGFR4—prostate cancer	2.44e-05	0.00059	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PARP1—prostate cancer	2.44e-05	0.00059	CbGpPWpGaD
Fluocinonide—Triamcinolone—PTGS2—prostate cancer	2.42e-05	0.00867	CrCbGaD
Fluocinonide—SMO—Signaling Pathways—CALCA—prostate cancer	2.41e-05	0.000583	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CXCL12—prostate cancer	2.35e-05	0.000569	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—prostate cancer	2.35e-05	0.000569	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CREBBP—prostate cancer	2.34e-05	0.000568	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—TBX5—prostate cancer	2.34e-05	0.000567	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PIK3CG—prostate cancer	2.24e-05	0.000542	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CASP9—prostate cancer	2.22e-05	0.000536	CbGpPWpGaD
Fluocinonide—Fluticasone Propionate—CYP3A4—prostate cancer	2.21e-05	0.00791	CrCbGaD
Fluocinonide—NR3C1—Gene Expression—EIF3H—prostate cancer	2.18e-05	0.000527	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—TP53—prostate cancer	2.17e-05	0.000525	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—NGFR—prostate cancer	2.15e-05	0.00052	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PRKCQ—prostate cancer	2.15e-05	0.00052	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MAP3K7—prostate cancer	2.12e-05	0.000513	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FGF10—prostate cancer	2.04e-05	0.000494	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—NCOA2—prostate cancer	2.04e-05	0.000493	CbGpPWpGaD
Fluocinonide—Dexamethasone—NR3C1—prostate cancer	2.03e-05	0.00728	CrCbGaD
Fluocinonide—Betamethasone—CYP3A4—prostate cancer	2.02e-05	0.00725	CrCbGaD
Fluocinonide—SMO—Signaling Pathways—ADRB2—prostate cancer	2.02e-05	0.000489	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—CTNNB1—prostate cancer	1.99e-05	0.000481	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL6—prostate cancer	1.99e-05	0.000481	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—MAP2K1—prostate cancer	1.98e-05	0.00048	CbGpPWpGaD
Fluocinonide—Betamethasone—PTGS2—prostate cancer	1.98e-05	0.0071	CrCbGaD
Fluocinonide—SMO—Signaling by GPCR—PIK3CD—prostate cancer	1.97e-05	0.000477	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—VAV3—prostate cancer	1.97e-05	0.000476	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—PARP1—prostate cancer	1.97e-05	0.000476	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—CDKN1A—prostate cancer	1.94e-05	0.00047	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TGFBR2—prostate cancer	1.94e-05	0.00047	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—prostate cancer	1.91e-05	0.000463	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ITPR1—prostate cancer	1.91e-05	0.000462	CbGpPWpGaD
Fluocinonide—Dexamethasone—CYP2E1—prostate cancer	1.87e-05	0.0067	CrCbGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—ESR2—prostate cancer	1.86e-05	0.000451	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CXCL8—prostate cancer	1.86e-05	0.000451	CbGpPWpGaD
Fluocinonide—Dexamethasone—CYP2C19—prostate cancer	1.85e-05	0.00663	CrCbGaD
Fluocinonide—Dexamethasone—CYP1A1—prostate cancer	1.84e-05	0.00661	CrCbGaD
Fluocinonide—SMO—Signaling Pathways—IGF1R—prostate cancer	1.83e-05	0.000442	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—JAK2—prostate cancer	1.81e-05	0.000438	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CASP3—prostate cancer	1.78e-05	0.000431	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—TET2—prostate cancer	1.77e-05	0.00043	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—MBD2—prostate cancer	1.77e-05	0.00043	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—LPL—prostate cancer	1.75e-05	0.000424	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IL6—prostate cancer	1.75e-05	0.000424	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—RPL12—prostate cancer	1.74e-05	0.000421	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PDGFRB—prostate cancer	1.73e-05	0.00042	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—STAT3—prostate cancer	1.73e-05	0.000419	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	1.72e-05	0.000416	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PIK3CB—prostate cancer	1.72e-05	0.000416	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—NCOA1—prostate cancer	1.72e-05	0.000416	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ITGB3—prostate cancer	1.69e-05	0.000409	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CXCL8—prostate cancer	1.65e-05	0.000399	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—AR—prostate cancer	1.65e-05	0.000398	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ERBB3—prostate cancer	1.64e-05	0.000397	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FGFR2—prostate cancer	1.64e-05	0.000396	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—RXRA—prostate cancer	1.63e-05	0.000395	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—prostate cancer	1.63e-05	0.000395	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—AKT1—prostate cancer	1.61e-05	0.000391	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—TGFB1—prostate cancer	1.61e-05	0.000389	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—EIF3A—prostate cancer	1.6e-05	0.000387	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—EP300—prostate cancer	1.6e-05	0.000387	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL2—prostate cancer	1.58e-05	0.000382	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TERT—prostate cancer	1.57e-05	0.00038	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—VEGFA—prostate cancer	1.51e-05	0.000366	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—HIF1A—prostate cancer	1.5e-05	0.000364	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—VDR—prostate cancer	1.48e-05	0.000358	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—LEP—prostate cancer	1.47e-05	0.000355	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CAV1—prostate cancer	1.45e-05	0.000352	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KDR—prostate cancer	1.44e-05	0.000348	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ESR1—prostate cancer	1.4e-05	0.000339	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—BAD—prostate cancer	1.37e-05	0.000331	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—DNMT3B—prostate cancer	1.34e-05	0.000326	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—APC—prostate cancer	1.32e-05	0.00032	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CG—prostate cancer	1.32e-05	0.00032	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—RPL10—prostate cancer	1.32e-05	0.000319	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—EGF—prostate cancer	1.31e-05	0.000317	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IRS1—prostate cancer	1.31e-05	0.000317	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—HIST1H2BG—prostate cancer	1.29e-05	0.000313	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—GSK3B—prostate cancer	1.27e-05	0.000307	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—INS—prostate cancer	1.25e-05	0.000303	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—HIST1H4H—prostate cancer	1.25e-05	0.000303	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—NPPA—prostate cancer	1.25e-05	0.000303	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—PPARA—prostate cancer	1.25e-05	0.000302	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—MED12—prostate cancer	1.23e-05	0.000298	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CREBBP—prostate cancer	1.23e-05	0.000297	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IGF1—prostate cancer	1.21e-05	0.000293	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—IL6—prostate cancer	1.21e-05	0.000293	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—EGFR—prostate cancer	1.21e-05	0.000292	CbGpPWpGaD
Fluocinonide—Dexamethasone—CYP3A4—prostate cancer	1.18e-05	0.00422	CrCbGaD
Fluocinonide—SMO—Signaling Pathways—MAP2K1—prostate cancer	1.17e-05	0.000284	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CD—prostate cancer	1.16e-05	0.000282	CbGpPWpGaD
Fluocinonide—Dexamethasone—PTGS2—prostate cancer	1.15e-05	0.00413	CrCbGaD
Fluocinonide—SMO—Signaling Pathways—SERPINE1—prostate cancer	1.15e-05	0.000279	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—KRAS—prostate cancer	1.14e-05	0.000276	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—ESR1—prostate cancer	1.13e-05	0.000274	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FGF2—prostate cancer	1.11e-05	0.00027	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—NOS3—prostate cancer	1.1e-05	0.000266	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—JAK2—prostate cancer	1.07e-05	0.000259	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PIK3CA—prostate cancer	1.05e-05	0.000253	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—IL6—prostate cancer	1.05e-05	0.000253	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—RPS19—prostate cancer	1.05e-05	0.000253	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MDM2—prostate cancer	1.04e-05	0.000252	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ERBB2—prostate cancer	1.03e-05	0.000249	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CB—prostate cancer	1.01e-05	0.000246	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—DNMT1—prostate cancer	9.99e-06	0.000242	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—CREBBP—prostate cancer	9.91e-06	0.00024	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—NCOA2—prostate cancer	9.81e-06	0.000237	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CXCL8—prostate cancer	9.75e-06	0.000236	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—EZH2—prostate cancer	9.68e-06	0.000234	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CDKN1B—prostate cancer	9.52e-06	0.00023	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—PARP1—prostate cancer	9.47e-06	0.000229	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CASP3—prostate cancer	9.33e-06	0.000226	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL2—prostate cancer	9.32e-06	0.000225	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—SERPINE1—prostate cancer	9.29e-06	0.000225	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL6—prostate cancer	9.27e-06	0.000224	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CCND1—prostate cancer	9.08e-06	0.00022	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CTNNB1—prostate cancer	8.99e-06	0.000218	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—ESR2—prostate cancer	8.97e-06	0.000217	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—HSPA1A—prostate cancer	8.97e-06	0.000217	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MMP9—prostate cancer	8.82e-06	0.000213	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CDKN1A—prostate cancer	8.79e-06	0.000213	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PTEN—prostate cancer	8.77e-06	0.000212	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—AKT1—prostate cancer	8.55e-06	0.000207	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—EP300—prostate cancer	8.36e-06	0.000202	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—NCOA1—prostate cancer	8.27e-06	0.0002	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—SRC—prostate cancer	8.13e-06	0.000197	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—AR—prostate cancer	7.93e-06	0.000192	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—VEGFA—prostate cancer	7.92e-06	0.000192	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—RXRA—prostate cancer	7.86e-06	0.00019	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—STAT3—prostate cancer	7.84e-06	0.00019	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MYC—prostate cancer	7.28e-06	0.000176	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TGFB1—prostate cancer	7.27e-06	0.000176	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—SIRT1—prostate cancer	7.23e-06	0.000175	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—EGFR—prostate cancer	7.12e-06	0.000172	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—VDR—prostate cancer	7.12e-06	0.000172	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KRAS—prostate cancer	6.73e-06	0.000163	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—ERCC2—prostate cancer	6.51e-06	0.000158	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CA—prostate cancer	6.18e-06	0.00015	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—PPARA—prostate cancer	6.01e-06	0.000145	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TP53—prostate cancer	5.98e-06	0.000145	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—MYC—prostate cancer	5.88e-06	0.000142	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL6—prostate cancer	5.48e-06	0.000133	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—ESR1—prostate cancer	5.44e-06	0.000132	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—AKT1—prostate cancer	5.05e-06	0.000122	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—CREBBP—prostate cancer	4.77e-06	0.000115	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—SERPINE1—prostate cancer	4.47e-06	0.000108	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—MYC—prostate cancer	2.83e-06	6.85e-05	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—AKT1—prostate cancer	1.96e-06	4.75e-05	CbGpPWpGaD
